, Figure 2. a) TPA decrease from baseline during follow-up. b) absolute TPA value during follow-up. c) BMI decrease during follow-up. d) Loss of weight during follow-up
Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012. ,
Cancer statistics, CA Cancer J Clin, vol.65, issue.1, pp.5-29, 2015. ,
,
, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, issue.11, pp.2913-2934, 2014.
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?, Ann Oncol, vol.26, issue.4, pp.779-86, 2015. ,
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?, Eur J Cancer, vol.34, issue.4, pp.503-512, 1998. ,
The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy, J Pain Symptom Manage, vol.48, issue.1, pp.13-25, 2014. ,
,
, Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer, J Clin Oncol, vol.34, issue.12, pp.1339-1383, 2016.
Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, issue.5, pp.489-95, 2011. ,
Epidemiology of Sarcopenia among the Elderly in New Mexico, Am J Epidemiol, vol.147, issue.8, pp.755-63, 1998. ,
Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery, Br J Cancer, vol.107, issue.6, pp.931-937, 2012. ,
Sarcopenia Impacts on Short-and Long-term Results of Hepatectomy for Hepatocellular Carcinoma, Ann Surg, vol.261, issue.6, pp.1173-83, 2015. ,
Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image A Step-by-Step Guide for Clinicians Using National Institutes of Health ImageJ, J Parenter Enter Nutr, vol.40, issue.3, pp.308-326, 2016. ,
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index, J Clin Oncol, vol.31, issue.12, pp.1539-1586, 2013. ,
Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer, Clin Cancer Res, vol.15, issue.22, pp.6973-6982, 2009. ,
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer, Surgery, vol.141, issue.5, pp.610-618, 2007. ,
Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis, Ann Surg Oncol, vol.15, issue.1, pp.165-74, 2008. ,
The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma, Am Surg, vol.70, issue.3, pp.235-275, 2004. ,
Margin clearance and outcome in resected pancreatic cancer, J Clin Oncol, vol.27, issue.17, pp.2855-62, 2009. ,
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704, J Clin Oncol, vol.26, issue.36, pp.5918-5940, 2008. ,
DOI : 10.1200/jco.2008.18.6288
URL : http://europepmc.org/articles/pmc2645109?pdf=render
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1842, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial, World Health Organ Tech Rep Ser, vol.31, issue.1, pp.1-253, 2000. ,
URL : https://hal.archives-ouvertes.fr/hal-01795555
Linear Mixed Models for Longitudinal Data, 2000. ,
Extending the Cox model, Mayo Clinic, 1996. ,
DOI : 10.1007/978-1-4684-6316-3_5
A bootstrap resampling procedure for model building: application to the Cox regression model, Stat Med, vol.11, issue.16, pp.2093-109, 1992. ,
DOI : 10.1002/sim.4780111607
Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator, Am Stat, vol.59, issue.4, pp.301-308, 2005. ,
Intraclass correlations: uses in assessing rater reliability, Psychol Bull, vol.86, issue.2, pp.420-428, 1979. ,
DOI : 10.1037//0033-2909.86.2.420
Statistical methods for rates and proportions, pp.38-46 ,
Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography, J Appl Physiol, vol.85, issue.1, pp.115-137, 1998. ,
DOI : 10.1152/jappl.1998.85.1.115
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, vol.9, issue.7, pp.629-664, 2008. ,
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, vol.33, issue.5, pp.997-1006, 2008. ,
Impact Total Psoas Volume on Short-and LongTerm Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia, J Gastrointest Surg, vol.19, issue.9, pp.1593-602, 2015. ,
Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index, PLoS ONE, vol.10, issue.10, 2015. ,
Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with GemcitabineBased Chemotherapy, Cancer Res Treat, 2016. ,
DOI : 10.4143/crt.2015.250
URL : http://e-crt.org/upload/pdf/crt-2015-060.pdf
,
, Références de la thèse
,
, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, vol.74, issue.11, pp.2913-2934, 2014.
Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012. ,
Cancer statistics, CA Cancer J Clin, vol.65, issue.1, pp.5-29, 2015. ,
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?, Ann Oncol, vol.26, issue.4, pp.779-86, 2015. ,
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?, Eur J Cancer, vol.34, issue.4, pp.503-512, 1998. ,
The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy, J Pain Symptom Manage, vol.48, issue.1, pp.13-25, 2014. ,
Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer, J Clin Oncol, vol.34, issue.12, pp.1339-1383, 2016. ,
Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, issue.5, pp.489-95, 2011. ,
Epidemiology of Sarcopenia among the Elderly in New Mexico, Am J Epidemiol, vol.147, issue.8, pp.755-63, 1998. ,
Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery, Br J Cancer, vol.107, issue.6, pp.931-937, 2012. ,
Sarcopenia Impacts on Short-and Long-term Results of Hepatectomy for Hepatocellular Carcinoma, Ann Surg, vol.261, issue.6, pp.1173-83, 2015. ,
Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image A Step-by-Step Guide for Clinicians Using National Institutes of Health ImageJ, J Parenter Enter Nutr, vol.40, issue.3, pp.308-326, 2016. ,
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index, J Clin Oncol, vol.31, issue.12, pp.1539-1586, 2013. ,
Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer, Clin Cancer Res, vol.15, issue.22, pp.6973-6982, 2009. ,
Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature, Nutr J, vol.9, p.69, 2010. ,
Pancreatic cancer surgery and nutrition management: a review of the current literature, Hepatobiliary Surg Nutr, vol.4, issue.1, pp.59-71, 2015. ,
Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non-Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care, J Clin Oncol, vol.29, issue.17, pp.2319-2345, 2011. ,
Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer, Pancreatol Off J Int Assoc Pancreatol IAP Al, vol.13, issue.5, pp.539-582, 2013. ,
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA, vol.310, issue.14, pp.1473-81, 2013. ,
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?, The Oncologist, vol.19, issue.3, pp.266-74, 2014. ,
, Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDASPRODIGE 44)-Full Text View-ClinicalTrials, 2016.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, vol.15, issue.6, pp.2403-2416, 1997. ,
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors, Ann Oncol Off J Eur Soc Med Oncol ESMO, vol.14, issue.3, pp.481-490, 2003. ,
Irinotecan plus oxaliplatin and leucovorinmodulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.6, pp.1228-1264, 2005. ,
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1842, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00598658
, Cancer du pancréas | SNFGE.org-Société savante médicale française d'hépatogastroentérologie et d'oncologie digestive, 2016.
Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association, Gastroenterology, vol.146, issue.1, pp.291-304, 2014. ,
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.56-68, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01810223
Imaging preoperatively for pancreatic adenocarcinoma, J Gastrointest Oncol, vol.6, issue.4, pp.343-57, 2015. ,
Sarcopenia is prevalent in patients with Crohn's disease in clinical remission, Inflamm Bowel Dis, vol.14, issue.11, pp.1562-1570, 2008. ,
Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma, J Gastrointest Surg Off J Soc Surg Aliment Tract, vol.16, issue.8, pp.1478-86, 2012. ,
Impact Total Psoas Volume on Short-and LongTerm Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia, J Gastrointest Surg, vol.19, issue.9, pp.1593-602, 2015. ,
Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index, PLoS ONE, vol.10, issue.10, 2015. ,
Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with GemcitabineBased Chemotherapy, Cancer Res Treat, 2016. ,
,
Statistical methods for rates and proportions, pp.38-46 ,
Outil de calcul du score de TPA (Total Psoas Area) en ligne ,
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials, Lancet Oncol, vol.17, issue.4, pp.519-550, 2016. ,